Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

AtriCure Inc Stock Research

ATRC

41.12USD-0.62(-1.49%)Market Closed
Watchlist

Market Summary

USD41.12-0.62
Market Closed
-1.49%

ATRC Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

ATRC Stock Price

ATRC RSI Chart

ATRC Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-69.45

Price/Sales (Trailing)

5.32

EV/EBITDA

-148.08

Price/Free Cashflow

-109.98

ATRC Price/Sales (Trailing)

ATRC Profitability

Operating Margin

74.42%

EBT Margin

-10.73%

Return on Equity

-8.3%

Return on Assets

-6.48%

Free Cashflow Yield

-0.91%

ATRC Fundamentals

ATRC Revenue

Revenue (TTM)

365.7M

Revenue Y/Y

19.39%

Revenue Q/Q

7.94%

ATRC Earnings

Earnings (TTM)

-28.0M

Earnings Y/Y

65.51%

Earnings Q/Q

20.97%

Price Action

52 Week Range

32.5159.61
(Low)(High)

Last 7 days

-7.9%

Last 30 days

-12.4%

Last 90 days

-14.1%

Trailing 12 Months

-1.4%

ATRC Financial Health

Current Ratio

3.81

ATRC Investor Care

Shares Dilution (1Y)

3.63%

Diluted EPS (TTM)

-0.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ATRC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-06
Wirick Angela L
sold (taxes)
-297,081
57.23
-5,191
chief financial officer
2023-08-04
CARREL MICHAEL H
gifted
-
-
-1,250
president, ceo, & director
2023-07-26
Dahlquist Karl S.
sold
-195,077
57.09
-3,417
chief legal officer
2023-06-30
Noznesky Justin J
acquired
20,846
38.11
547
chief mktg & strategy officer
2023-06-30
Seith Douglas J
acquired
21,227
38.11
557
chief operating officer
2023-06-30
Dahlquist Karl S.
acquired
21,227
38.11
557
chief legal officer
2023-06-30
CARREL MICHAEL H
acquired
21,227
38.11
557
president, ceo, & director
2023-06-30
Yount Deborah Lee
acquired
17,149
38.11
450
chief human resources officer
2023-06-30
Privitera Salvatore
acquired
21,227
38.11
557
chief technical officer
2023-06-30
Doraiswamy Vinayak
acquired
21,227
38.11
557
chief scientific officer

1–10 of 50

Which funds bought or sold ATRC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
unchanged
-
775
4,837
-%
2023-09-20
BARCLAYS PLC
reduced
-24.01
-108,000
1,025,000
-%
2023-08-22
COMERICA BANK
new
-
96,000
96,000
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
added
0.78
113,035
677,630
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
2.55
511,428
2,823,340
-%
2023-08-18
Legato Capital Management LLC
added
39.62
495,253
1,242,640
0.17%
2023-08-17
Orion Portfolio Solutions, LLC
reduced
-6.03
393,699
3,700,120
0.04%
2023-08-16
Nuveen Asset Management, LLC
added
41.24
19,635,300
48,430,300
0.02%
2023-08-15
GOLDMAN SACHS GROUP INC
added
10.07
3,065,170
12,927,600
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
unchanged
-
14,000
89,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying ATRC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATRC
No. of Funds

Schedule 13G FIlings of AtriCure

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
alliancebernstein l.p.
7.7%
3,565,726
SC 13G/A
Feb 14, 2023
alger associates inc
3.8%
1,755,398
SC 13G/A
Feb 09, 2023
vanguard group inc
9.44%
4,389,815
SC 13G/A
Feb 03, 2023
blackrock inc.
8.0%
3,735,766
SC 13G/A
Feb 03, 2023
invesco ltd.
7.2%
3,367,324
SC 13G/A
Feb 14, 2022
alger associates inc
7.1%
3,240,847
SC 13G/A
Feb 14, 2022
alliancebernstein l.p.
7.5%
3,455,856
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
4.2%
1,945,751
SC 13G/A
Feb 09, 2022
vanguard group inc
9.22%
4,234,298
SC 13G/A
Feb 09, 2022
invesco ltd.
5.3%
2,437,617
SC 13G/A

Recent SEC filings of AtriCure

View All Filings
Date Filed Form Type Document
Aug 17, 2023
144
Notice of Insider Sale Intent
Aug 08, 2023
4
Insider Trading
Aug 08, 2023
4
Insider Trading
Jul 28, 2023
4
Insider Trading
Jul 26, 2023
S-8
Employee Benefits Plan
Jul 26, 2023
S-8
Employee Benefits Plan
Jul 26, 2023
144
Notice of Insider Sale Intent
Jul 26, 2023
10-Q
Quarterly Report
Jul 25, 2023
8-K
Current Report
Jul 03, 2023
4
Insider Trading

Peers (Alternatives to AtriCure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
101.2B
6.7B
-0.75% 50.83%
71.05
15.19
11.75% -0.66%
77.5B
13.4B
6.45% 36.39%
85
5.78
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.3B
5.7B
-8.22% -17.24%
30.48
7.49
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
7.1B
616.6M
-12.54% -24.86%
29.24
11.56
69.52% 343.68%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
1.3B
790.3M
-27.09% -56.49%
-5.97
1.69
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-15.15% 56.11%
-9.32
3.69
44.49% -2.43%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
609.7M
162.9M
-27.67% -61.65%
-11.53
3.74
42.67% 12.82%

AtriCure News

Best Stocks
Positive Outlook for AtriCure, Inc. (NASDAQ:ATRC) despite Insider ....
Best Stocks,
8 hours ago
Mundurowe Wiadomości
StreetInsider.com
Clayton County Register

Returns for ATRC

Cumulative Returns on ATRC

14.4%


10-Year Cumulative Returns

14.3%


7-Year Cumulative Returns

3.1%


5-Year Cumulative Returns

1.8%


3-Year Cumulative Returns

Risks for ATRC

What is the probability of a big loss on ATRC?

90%


Probability that AtriCure stock will be more than 20% underwater in next one year

53.9%


Probability that AtriCure stock will be more than 30% underwater in next one year.

37.7%


Probability that AtriCure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATRC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AtriCure was unfortunately bought at previous high price.

Drawdowns

Financials for AtriCure

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue4.7%365,686,000349,297,000330,379,000315,569,000302,783,000289,630,000274,329,000258,836,000243,133,000212,581,000206,531,000210,127,000211,984,000230,066,000230,807,000222,379,000215,706,000208,602,000201,630,000194,799,000187,008,000
Cost Of Revenue3.2%92,174,00089,343,00084,439,00079,726,00076,427,00072,715,00068,469,00065,555,00061,744,00057,616,00057,222,00058,481,00058,875,00060,718,00060,472,00058,228,00057,404,00056,114,00054,510,00053,586,00050,825,000
Gross Profit5.2%273,512,000259,954,000245,940,000235,843,000226,356,000216,915,000205,860,000193,281,000181,389,000154,965,000149,309,000151,646,000153,109,000169,348,000170,335,000164,151,000158,302,000152,488,000147,120,000141,213,000136,183,000
Operating Expenses1.4%298,297,000294,255,000288,609,000286,878,000167,999,000159,975,000150,655,000143,077,000233,845,000199,629,000193,542,000193,702,000199,811,000212,604,000203,457,000184,554,000176,116,000165,505,000164,247,000157,868,000153,637,000
  S&GA Expenses0.6%236,615,000235,220,000231,272,000229,481,000222,087,000216,657,000204,649,000200,611,000184,295,000152,240,000150,829,000153,131,000159,854,000172,879,000167,143,000147,965,000141,125,000131,663,000129,524,000123,879,000120,238,000
  R&D Expenses4.5%61,682,00059,035,00057,337,00057,397,00053,512,00050,918,00048,506,00045,569,00044,861,00042,700,00043,070,00045,295,00044,873,00044,641,00041,230,00036,589,00034,991,00033,842,00034,723,00033,989,00033,399,000
EBITDA100.0%--23,480,000-33,155,000-43,590,00065,748,00064,420,00062,839,00058,241,000-43,920,000-43,681,000-43,156,000-40,677,000-45,130,000-41,349,000-30,884,000------
EBITDA Margin100.0%--0.07-0.10-0.140.220.220.230.23-0.18-0.21-0.21-0.19-0.21-0.18-0.13------
Interest Expenses11.0%6,240,0005,622,0004,986,0004,508,0004,633,0004,729,0004,918,0005,029,0004,812,0004,846,0004,885,0004,948,0004,829,0004,477,0004,111,0004,174,0004,307,0004,649,0004,607,0003,857,0003,187,000
Earnings Before Taxes26.1%-27,698,000-37,469,000-46,198,000-55,837,00053,535,00052,146,00050,387,00045,611,000-56,488,000-48,527,000-48,041,000-45,625,000-49,959,000-45,826,000-34,995,000-22,298,000-20,195,000-16,394,000-20,911,000-20,192,000-20,228,000
EBT Margin100.0%--0.11-0.14-0.180.180.180.180.18-0.23-0.23-0.23-0.22-0.24-0.20-0.15------
Net Income25.8%-28,036,000-37,759,000-46,466,000-56,037,00053,343,00051,933,00050,199,00045,378,000-56,679,000-48,664,000-48,155,000-45,689,000-50,102,000-45,967,000-35,194,000-22,528,000-20,401,000-16,638,000-21,137,000-20,287,000-20,298,000
Net Income Margin100.0%--0.11-0.14-0.180.180.180.180.18-0.23-0.23-0.23-0.22-0.24-0.20-0.15------
Free Cashflow100.0%--17,590,000-39,022,000-37,306,000-32,113,000-40,904,000-23,533,000-18,222,000-13,937,000-17,851,000-25,128,000-35,916,000-44,424,000-30,765,000-27,993,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets1.9%594583585582587585615613701700715708704528558561343338357272271
  Current Assets-0.1%23823821521220620019619623629830729629212714313814715517588.0087.00
    Cash Equivalents-13.1%67.0077.0058.0049.0055.0028.0044.0040.0068.0085.0042.0033.0089.0022.0028.0033.0025.0021.0032.0018.0014.00
  Inventory13.4%55.0049.0046.0044.0041.0041.0039.0039.0038.0036.0035.0034.0033.0032.0029.0028.0024.0024.0022.0022.0022.00
  Net PPE----39.0036.0033.0031.0030.0030.0028.0028.0029.0030.0032.0033.0031.0028.0027.0027.0028.0028.00
  Goodwill0%235235235235235235235235235235235235235235235236105105105105105
Liabilities2.7%13212812913213112213212531630930229028730031130310299.00107108111
  Current Liabilities14.3%71.0062.0058.0058.0056.0047.0056.0054.0067.0058.0049.0045.0038.0039.0050.0044.0039.0035.0040.0034.0027.00
    LT Debt, Non Current-9.4%47.0052.0057.0060.0060.0060.0060.0056.0044.0049.0053.0050.0054.0058.0060.0060.0034.0033.0036.0039.0039.00
Shareholder's Equity1.7%462455457450457463484488385391412418417227247258242239249164160
  Retained Earnings-1.5%-338-333-326-322-310-295-280-266-363-347-330-311-306-298-282-266-256-252-247-243-236
  Additional Paid-In Capital1.5%803791787778771762765755749738742729724526530525498492497407396
Shares Outstanding0.2%47.0047.0047.0046.0046.0046.0046.0045.0045.0045.0045.0044.0040.0039.0040.0038.0037.0037.0034.0034.0033.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-76.7%-2.81-1.59-22.14-21.89-20.33-29.10-13.78-10.13-6.08-13.10-19.87-27.35-33.75-18.46-15.81-11.30-3.49-8.18-4.17-3.63-8.71
  Share Based Compensation4.8%32.0030.0029.0029.0029.0029.0028.0027.0026.0025.0023.0021.0020.0018.0018.0018.0018.0017.0016.0015.0015.00
Cashflow From Investing-68.9%16.0053.0044.0038.0016.00-20.3624.0020.00-13.19-109-156-156-1074.00-2.15-70.37-61.34-70.14-85.40-13.51-15.51
Cashflow From Financing54.5%-0.95-2.08-7.06-6.53-8.39-7.43-7.64-3.70-1.7418718918420516.0014.0097.0076.0078.0010016.0017.00

ATRC Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 100,918$ 84,529$ 194,412$ 159,105
Cost of revenue23,84121,01047,72639,991
Gross profit77,07763,519146,686119,114
Operating expenses:    
Research and development expenses17,43814,79132,76528,420
Selling, general and administrative expenses63,78362,388123,847118,504
Total operating expenses81,22177,179156,612146,924
Loss from operations(4,144)(13,660)(9,926)(27,810)
Other income (expense):    
Interest expense(1,719)(1,101)(3,355)(2,101)
Interest income961761,836192
Other(123)(111)22(204)
Loss before income tax expense(5,025)(14,796)(11,423)(29,923)
Income tax expense9345171101
Net loss$ (5,118)$ (14,841)$ (11,594)$ (30,024)
Net (loss) income per share    
Basic net loss per common share (in usd per share)$ (0.11)$ (0.32)$ (0.25)$ (0.66)
Diluted net loss per common share (in usd per share)$ (0.11)$ (0.32)$ (0.25)$ (0.66)
Weighted average shares outstanding    
Weighted average shares outstanding—basic (in shares)46,26645,69246,18745,610
Weighted average shares outstanding—diluted (in shares)46,26645,69246,18745,610
Comprehensive income (loss):    
Unrealized gain (loss) on investments$ 427$ (449)$ 1,468$ (2,788)
Foreign currency translation adjustment36(430)19(608)
Other comprehensive income (loss)463(879)1,487(3,396)
Net loss(5,118)(14,841)(11,594)(30,024)
Comprehensive loss, net of tax$ (4,655)$ (15,720)$ (10,107)$ (33,420)

ATRC Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 67,240$ 58,099
Short-term investments59,78563,014
Accounts receivable, less allowance for credit losses of $23048,36242,693
Inventories55,40945,931
Prepaid and other current assets7,1795,477
Total current assets237,975215,214
Long-term investments7,59851,509
Property and equipment, net40,54038,833
Operating lease right-of-use assets4,3533,787
Intangible assets, net67,38339,339
Goodwill234,781234,781
Other noncurrent assets1,5411,985
Total assets594,171585,448
Current liabilities:  
Accounts payable23,70919,898
Accrued liabilities31,98633,022
Current maturities of debt and leases15,7155,472
Total current liabilities71,41058,392
Long-term debt47,04756,834
Finance lease liabilities8,6149,147
Operating lease liabilities3,4583,095
Other noncurrent liabilities1,2201,226
Total liabilities131,749128,694
Commitments and contingencies (Note 9)
Stockholders’ Equity:  
Common stock, $0.001 par value, 90,000 shares authorized and 47,352 and 46,563 issued and outstanding4747
Additional paid-in capital803,197787,422
Accumulated other comprehensive loss(2,609)(4,096)
Accumulated deficit(338,213)(326,619)
Total stockholders’ equity462,422456,754
Total liabilities and stockholders’ equity$ 594,171$ 585,448
Michael H. Carrel
880
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.